OUP user menu

Cardio NewsWire

Please click here to view the archive of previous Cardio NewsWire stories. Each item is removed from the archive after 90 days. 

“Ten Commandments” of 2015 ESC Infective Endocarditis Guidelines

“Ten Commandments” of 2015 ESC Acute Coronary Syndromes Guidelines

“Ten Commandments” of 2015 ESC Pericardial Diseases Guidelines

“Ten Commandments” of 2015 ESC Pulmonary Hypertension Guidelines

“Ten Commandments” of 2015 ESC Ventricular Arrhythmias and Prevention of SCD Guidelines 

A Day with the Legends, ESC Congress 2015

Lightning Talks at ESC London

The Russian National Congress of Cardiology 2015

 

Two sets of “Ten Commandments” are presented with some overlap for this very serious condition, Infective Endocarditis, which has a grave prognosis and mortality even in the 21st century.

“Ten Commandments” presented by ESC Task Force member Barbara JM Mulder MD

  1. Antibiotic prophylaxis should be restricted to highest-risk patients, but preventive measures should be maintained or extended, to all patients with cardiac disease.
  2. Echocardiography (TTE and TOE), positive blood cultures and clinical features remain the cornerstone for the diagnosis of IE and new imaging modalities (MRI, CT, PET/CT) may allow the diagnosis of embolic events and of cardiac involvement when TTE/TOE are negative or doubtful.
  3. Prognostic assessment at admission, using simple clinical, microbiological, and echocardiographic parameters, should be used to select the best initial approach; patients with persistently positive blood cultures after 48–72 h of starting antibiotics have a worse prognosis.
  4. Heart failure is the most frequent and among the most severe complication of IE and is an indication for early surgery in native and prosthetic valve endocarditis, even in patients with cardiogenic shock.
  5. Uncontrolled infection is most frequently related to peri-valvular extension or ‘difficult-to-treat’ organisms and is an indication for early surgery.
  6. The risk of embolism is highest during the first 2 weeks of antibiotic therapy and the decision to operate early to prevent embolism should depend on size and mobility of the vegetation, previous embolism, type of microorganism, and duration of antibiotic therapy.
  7. After a first neurological event, cardiac surgery, if indicated, is generally not contraindicated, except when extensive brain damage or intracranial haemorrhage is present.
  8. Recurrences are rare following IE, and may be associated with inadequate initial antibiotic therapy, resistant microorganisms, a persistent focus of infection, intravenous drug abuse, and chronic dialysis.
  9. Complicated and staphylococcal prosthetic valve endocarditis are associated with a worse prognosis and must be managed aggressively; patients with non-complicated, non-staphylococcal late prosthetic valve endocarditis can be managed conservatively with close follow-up.
  10. Cardiac device-related IE must be suspected in the presence of frequently misleading symptoms: prognosis is poor, probably because of its frequent occurrence in elderly patients with associated comorbidities and must be treated by prolonged antibiotic therapy and device removal.

Barbara JM Mulder MD

ESC Task Force member

b.j.mulder@amc.uva.nl

 

“Ten Commandments” presented by ESC Task Force member, co-chair and chair.

  1. Creation of an “Endocarditis Team”. A multidisciplinary approach is mandatory, to include cardiologists, cardiac surgeons and specialists of infectious diseases.
  2. The creation of referral Endocarditis Centres is recommended due to the severity of the disease. Centres with experience in complex surgery are the best place to treat such patients.
  3. While echocardiography plays a key role in diagnostic algorithms, the need for a multimodality imaging approach for diagnosing endocarditis is highlighted. The new guidelines show the important diagnostic role of other imaging techniques, such as PET-CT that may be helpful in diagnosis and management decisions.
  4. The Early strategy in endocarditis is crucial:
    1. Early diagnosis,
    2. Early antibiotic therapy,
    3. Early surgery.
  5. Repeat TTE and /or TOE examination is recommended within 5–7 days in case of initially negative examination when clinical suspicion of IE remains high, or as soon as a new complication of IE is suspected (new murmur, embolism, persisting fever, heart failure, abscess, atrioventricular block).
  6. Prophylaxis is still controversial. Antibiotic prophylaxis should be considered for patients at highest risk for IE with a IIa recommendation. It should be considered in:

i) Patients with any prosthetic valve, including transcatheter valve, or those in whom any prosthetic material was used for cardiac valve repair.

ii) Patients with previous episode of IE.

iii) Patients with congenital heart disease:

a) Any type of cyanotic congenital heart disease or 

b) Any type of congenital heart disease repaired with a prosthetic material.

  1. New antibiotic strategies were proposed in staphylococcal endocarditis. A consensus was difficult to obtain in the subgroup of patients with the most severe form of IE. Ongoing studies on this topic will be useful.
  2. Urgent surgery in specialised Centres is recommended in cases with aortic or mitral native valve endocarditis (NVE) or prosthetic valve endocarditis (PVE) with severe regurgitation or obstruction causing symptoms of heart failure or echocardiographic signs of poor haemodynamic tolerance, must by treated by urgent surgery. It is also recommended in patients with locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation) or in infections caused by fungi or multiresistant organisms. Patients with aortic or mitral NVE or PVE with persistent vegetations >10 mm after ≥1 embolic episode despite appropriate antibiotic therapy must also be treated by urgent surgery.
  3. Special mention is made related to endocarditis in patients with cardiac devices (CDRIE). Prolonged (i.e. before and after extraction) antibiotic therapy and complete hardware (device and leads) removal are recommended. Percutaneous extraction is recommended in most patients with CDRIE, even those with vegetations >10 mm. In these patients routine antibiotic prophylaxis is recommended before device implantation.
  4. Related to patients with neurological complications. After a silent embolism or transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay.

José Luis Zamorano MD

ESC Task Force member

zamorano@secardiologia.es

Gilbert Habib MD

ESC Task Force Chairperson

Patrizio Lanzelloti MD

ESC Task Force co-Chairperson

“Ten Commandments” of 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in patients presenting without Persistent ST-Segment Elevation (NSTE-ACS)

  1. "Similar to the 0 h and 3 h protocol”, a rapid rule-out and rule-in protocol for myocardial infarction (MI) at 0 h and 1 h is recommended if a high-sensitivity troponin test with a validated 0 h/1 h algorithm is available. 
  2. Echocardiography is recommended to evaluate regional and global left ventricular (LV) function and to rule in or rule out differential diagnoses.
  3. A P2Y12 inhibitor is recommended in addition to aspirin for 12 months, unless there are contraindications such as excessive risk of bleeds. 
  4. Ticagrelor is recommended for all patients at moderate to high risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment strategy.
  5. Prasugrel is recommended in patients who are proceeding to percutaneous coronary intervention (PCI).
  6. Clopidogrel is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation.
  7. Antithrombotic strategies for patients requiring oral anticoagulation should be personalized, and the different combinations of oral anticoagulants with single or dual antiplatelet therapy and their variable duration be tailored on the basis of the patient's bleeding risk and management strategy. 
  8. An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very-high-risk criteria:

Haemodynamic instability or cardiogenic shock,
Recurrent or ongoing chest pain,
Refractory to medical treatment,
Life-threatening arrhythmias or cardiac arrest,
Mechanical complications of MI,
Acute heart failure with refractory angina or ST deviation,
Recurrent dynamic ST- or T-wave changes, particularly with intermittent ST elevation.

  1. An early invasive strategy (<24 h) is recommended in patients with at least one of the following high-risk criteria:

Rise or fall in troponin compatible with MI,
Dynamic ST- or T-wave changes (symptomatic or silent),
Registry of Acute Coronary Events (GRACE) score >140.

  1. An invasive strategy (<72 h) is recommended in patients with at least one of the following intermediate risk criteria:

Diabetes mellitus renal insufficiency (eGFR <60 mL/min/1.73 m2),
LV ejection fraction <40% or congestive heart failure,
Early post-infarction angina,
Recent PCI,
Prior coronary artery bypass grafting (CABG),
Global GRACE risk score >109 and <140,
Or, in the presence of recurrent symptoms or ischaemia on non-invasive testing.

  1. In centres experienced with radial access, a radial approach is recommended for coronary angiography and PCI. It is recommended that centres treating ACS patients implement a transition from transfemoral to transradial access. 
  2. In patients with multivessel coronary artery disease, it is recommended to base the revascularisation strategy (e.g. ad hoc culprit-lesion PCI, multivessel PCI, CABG) on the clinical status and comorbidities as well as the disease severity (including distribution, angiographic lesion characteristics, SYNTAX score) according to the local Heart Team protocol.
  3. It is recommended to start high-intensity statin therapy as early as possible unless contraindicated, and maintain it long-term.

Marco Roffi MD FESC
ESC Task Force chair
Division of Cardiology, University Hospital
Geneva, Switzerland
corresponding author

marco.roffi@hcuge.ch

Carlo Patrono MD
ESC Task Force co-chair
Istituto di Farmacologia
Università Cattolica del Sacro Cuore
Rome, Italy
cpatrono@unich.it

The “Ten Commandments” of the ESC Guidelines 2015 for Diagnosis and Management of Pericardial Diseases

1.   Hospital admission is recommended for high risk patients with acute pericarditis, defined by a risk factor of either predictor of a specific cause (non-viral or non-idiopathic) or of increased risk of complications.

At least one risk factor among: high fever (>38ºC), subacute course, large pericardial effusion, cardiac tamponade, failure to respond to non-steroidal anti-inflammatory drug (NSAID) therapy; myopericarditis, immunosuppression, trauma or oral anticoagulant therapy.

2.   Colchicine is recommended as a first line therapy for acute pericarditis as an adjunct to aspirin/NSAID therapy.

3.   Pericardiocentesis, or surgical drainage, is indicated for cardiac tamponade, or for symptomatic moderate to large pericardial effusions which do not respond to medical therapy and for suspicion of bacterial or neoplastic aetiology.

4.   The mainstay of treatment for chronic permanent constriction is pericardiectomy.

5.   A general diagnostic work-up should be performed to identify causes that require targeted therapies.  A modern approach for the management of pericardial diseases should include the integration of biological markers, as well as different imaging modalities.

6.   Routine viral serology is not recommended in acute pericarditis, with the possible exception of HIV and HCV.  For the definite diagnosis of viral pericarditis, a comprehensive work-up of histological, cytological, immunohistological and molecular investigations in pericardial fluid should be considered.  In the absence of such argument the term “presumed viral pericarditis” should be used.

7.   In patients living in non-endemic areas, empiric anti-tuberculosis treatment is not recommended when systematic investigation fails to yield a diagnosis of tuberculous pericarditis. By contrast, in patients living in endemic areas empiric antituberculosis chemotherapy is recommended for exudative pericardial effusion, after excluding other causes.

8.   Effective pericardial drainage is recommended for purulent pericarditis as well as administration of intravenous antibiotics.

9.   Cytological analyses of pericardial fluid are recommended for the confirmation of malignant pericardial disease. Pericardial or epicardial biopsy should be considered for the confirmation of malignant pericardial disease.

10.   Aspirin is not recommended for therapy of acute pericarditis in children but NSAIDs at high doses are recommended as first line therapy.

For more information see: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/essential-message-slideset.aspx

Philippe Charron MD PhD
ESC Task Force co-chair
First and corresponding author
philippe.charron@aphp.fr

Yehuda Adler MD MHA
ESC Task Force co-chair
adlery@sheba.health.gov.il

The “Ten Commandments” of the 2015 ESC-ERS Guidelines on Pulmonary Hypertension

  1. Right heart catheterization is recommended to confirm the diagnosis of pulmonary arterial hypertension (PAH - Group 1) and to support treatment decisions
  2. Vasoreactivity testing performed during right heart catheterization is recommended in patients with idiopathic PAH, inherited PAH and PAH induced by drugs or toxin use, to detect patients who can be treated with high doses of a calcium channel blocker
  3. It is recommended to evaluate the severity of PAH patients with a panel of data derived from clinical assessment, exercise tests, biochemical markers, and echocardiographic and haemodynamic evaluation and to perform regular follow-up assessments every 3-6 months in stable patients.
  4. It is recommended to avoid pregnancy in patients with PAH
  5. It is recommended for referral centres to provide care by a multi-professional team (cardiology and respiratory medicine physicians, clinical nurse specialist, radiologists, psychological and social work support, with appropriate on-call expertise)
  6. Initial drug monotherapy or initial oral drug combination therapy is recommended in treatment naïve, low or intermediate risk patients with PAH
  7. Sequential drug combination therapy is recommended in PAH patients with inadequate treatment response to initial monotherapy or to initial oral drug combination therapy.
  8. Initial combination therapy including an intravenous prostacyclin analogue is recommended in high risk PAH patients
  9. The use of PAH approved therapies is not recommended in patients with pulmonary hypertension due to left heart disease or lung diseases
  10. Surgical pulmonary endarterectomy in deep hypothermia circulatory arrest is recommended for patients with chronic thrombo-embolic pulmonary hypertension [CTEPH] and it is recommended that the assessment of operability and decisions regarding other treatment strategies (drugs therapy or balloon pulmonary angioplasty) be made by a multidisciplinary team of experts

Nazzareno Galiè MD
ESC Task Force chairperson

Marc Humbert MD PhD
ERS Task Force chairperson

“Ten Commandments” of the 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and Prevention of Sudden Cardiac Death

  1. Investigate individuals with known or suspected ventricular arrhythmias completely, applying both non-invasive and invasive techniques: a good etiological diagnosis is the first step towards efficient management of patients and the prevention of sudden cardiac death.
  2. Perform a complete autopsy in victims of sudden unexplained death, especially when they are young: the identification of an inheritable disease as the cause of death may prevent other tragedies within their family.
  3. Consider the use of an implantable cardioverter defibrillator (ICD) in all survivors of an episode of ventricular fibrillation or ventricular tachycardia accompanied by haemodynamic instability that occurs without apparent reversible causes or outside of the acute phase of myocardial infarction. These patients have a high incidence of recurrent life-threatening arrhythmias.
  4. Ensure that patients with STEMI acute coronary syndromes and unstable angina are urgently sent to reperfusion, especially when recurrent ventricular tachycardia and ventricular fibrillation are present: reducing delays from first medical contact to reperfusion helps prevent sudden cardiac death.
  5. Evaluate left ventricular ejection fraction both before discharge and 6–12 weeks after myocardial infarction: post-MI patients may benefit from ICD implantation for the primary prevention of sudden cardiac death.
  6. Implement optimal therapy including pharmacological agents (ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists) and, if appropriate, ICDs in patients with heart failure with severe systolic dysfunction (left ventricular ejection fraction ≤35%).
  7. Consider the addition of cardiac resynchronization therapy for patients with the previous characteristics, when they also have intraventricular conduction delays with left bundle branch block appearance and QRS duration of >120 ms.
  8. Updated diagnostic criteria for inherited arrhythmogenic syndromes, including Long QT Syndrome and Brugada Syndrome, have been proposed by the new guidelines. Please refer to them in your clinical practice.
  9. Consider catheter ablation in experienced centres as a valuable tool to treat patients presenting scar-related ventricular tachycardias, bundle branch re-entrant tachycardia or electrical storms.
  10. Discuss with your patients the issues related to the impact that ICDs may have on their quality of life, before the implant and during their disease progression. Consider the possibility of deactivating the ICD when their clinical conditions deteriorate. Always respect your patients’ autonomy.

Andrea Mazzanti MD
Molecular Cardiology
IRCCS Salvatore Maugeri Foundation
andrea.mazzanti@fsm.it

 

 

A Day with the Legends at ESC Congress 2015

Sunday 30 August in The Hub at Regents Park

08:30 to 09:10 - ESC Andreas Grüntzig Lecture on Interventional Cardiology

Interventional cardiology, where real life and science do not necessarily meet          

Bernard Meier (Bern, CH)

Chairman and Professor of Cardiology, Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland.
Swiss native. Trained at the medical school of the University of Zurich, Switzerland, graduated 1975 (best of 180). Board certified in internal medicine 1980 and cardiology 1983. Cardiology training at Emory University, Atlanta, Georgia, USA, with Andreas Grüntzig

1983 - 1992 Head of invasive cardiology, University Hospital, Geneva, Switzerland.
1992 - Chairman and Professor of Cardiology, University Hospital, Bern, Switzerland.
2001 - Rotating Chairman, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland.

Specialized in interventional cardiology. Involved in coronary angioplasty since the first case performed by Andreas Grüntzig on September 16, 1977 in Zurich, Switzerland. Author and co-author of numerous books, reviews, and original articles on cardiology, in particular interventional cardiology. Organizer and active participant of countless educational meetings on interventional cardiology. Fellow of the American College of Cardiology and of the European Society of Cardiology. Past president of the Swiss Society of Cardiology. Recipient of several awards.

09:20 to 10:00 - ESC William Harvey Lecture on Basic Science

Microcircular networks: the business end of the circulation

Axel Radlach Pries (Berlin, DE)

Axel Radlach Pries studied medicine at the University of Cologne and defended his doctoral thesis in 1980 with ‘summa cum laude’.

He worked as postdoctoral fellow in Cologne and Berlin University and 1997-1998 at the Institute of Anaesthesiology of the German Heart Center Berlin. 1998 he became full professor at the Department of Physiology, Free University Berlin and 2001 head of the Charité Institute for Physiology.

His scientific interests include microcirculation, tumour vasculature, blood rheology, vascular adaptation, angiogenesis, and the endothelial surface layer. He was general secretary of the ESM (European Society for Microcirculation) and is chair of the International Liaison Committee for Microcirculation.

In the ESC, he was chair of the Working Group for Coronary Pathophysiology and Microcirculation and the Council for Basic Cardiovascular Science (CBCS). Since 2015, he is Dean of the Charité University Medicine Berlin.

 

Meet the Legends

10:10 - 10:50 - Keith Fox (Edinburgh, UK)

He was a founding Fellow of the European Society of Cardiology and Chair of the Programme of the European Society of Cardiology 2012-2014.  In addition, he was President of the British Cardiovascular Society from 2009 to 2012.

His awards include the Silver Medal of the European Society of Cardiology in 2010 and again in 2014 and the Mackenzie medal of the British Cardiovascular Society (2013). Professor Fox’s major research interest lies in the mechanisms and manifestations of acute coronary arterial disease; his work extends from underlying biological mechanisms to in vitro and in vivo studies and clinical trials.

He is an International Associate Editor of the European Heart Journal and Deputy Editor of the Journal of the American College of Cardiology JACC (Europe).  His ongoing research interests include the mechanisms of inflammation and plaque rupture in acute coronary syndromes and antithrombotic therapies.

 

A Journey to Stockholm

11:00 - 12:30 - Ageing and cardiovascular disease: role of cellular senescence

Elisabeth Blackburn (San Francisco, US)

Professor Elizabeth H. Blackburn is a Nobel Laureate and Morris Herzstein Professor of Biology and Physiology, in the Department of Biochemistry and Biophysics at the University of California San Francisco (UCSF).

She is a leader in the area of telomere and telomerase research. Elizabeth Blackburn discovered the molecular nature of telomeres - the ends of eukaryotic chromosomes that serve as protective caps essential for preserving the genetic information - and co-discovered the ribonucleoprotein enzyme, telomerase. Professor Blackburn and her research team at UCSF are working with various cells including human cells, with the goal of understanding telomerase and telomere biology. They also collaborate in investigating the roles of telomere biology in human health and diseases, in clinical and other human studies.

Throughout her career, Professor Blackburn has won many prestigious awards. She was elected Fellow of the American Academy of Arts and Sciences (1991) and the Royal Society of London (1992). She was elected Foreign Associate of the National Academy of Sciences (1993) and Member of the Institute of Medicine (2000). She served on the President’s Council on Bioethics from 2002 to 2004, and has been awarded honorary degrees by 11 Universities. She received the Albert Lasker Medical Research Award for Basic Medical Research in 2006, and in 2007 was named one of TIME Magazine’s 100 Most Influential People. In 2008 she was the North American Laureate for L’Oreal-UNESCO For Women in Science.

In 2009, Professor Blackburn was awarded the Nobel Prize in Physiology or Medicine.

 

Meet the Legends

14:00 - 14:40 - Richard Popp (Palo Alto, US)

Dr. Richard Popp is Emeritus Professor of Medicine at Stanford University. Dr. Popp is a clinical cardiologist and teacher who focused his research on the development of all forms of ultrasound in cardiology with more than 300 scientific publications.  He has trained over 150 cardiologists through his clinical laboratory program.

Dr. Popp was Senior Associate Dean for Academic Affairs at Stanford from 1995-2000. He continues to teach in the Stanford Biodesign Innovation Program where he heads the Ethics and Policy group. He has been Chair, the Conflict of Interest Committee at the Medical School since 2000. 

Dr. Popp was President of the American College of Cardiology, the American Society of Echocardiography and the Association of University Cardiologists. He is the previous Chairman of the American Board of Internal Medicine’s Cardiovascular Diseases Sub-specialty Board. He is a Master of the American College of Cardiology and a Fellow of the American Heart Association, the American Society of Echocardiography, and the European Society of Cardiology. He has been given Honorary Fellowship in the Cardiology Society of several countries.

14:50 -15:30 Michel Haissaguerre (Pessac, FR)

16:30 - 17:10 - ESC Rene Laennec Lecture on Clinical Cardiology

The interaction of acute blood pressure change, pericardial restraint and acute outflow tract stretch - A new paradigm underlying sudden cardiac death
George Sutherland (London, UK)

 

 

17:20 -18:00 - ESC Geoffrey Rose Lecture on Population Sciences

Optimising cardiovascular health: old and new challenges

Kay-Tee Khaw (Cambridge, UK)

Kay Tee Khaw is Professor of Clinical Gerontology, University of Cambridge.   
She trained in medicine at Girton College, University of Cambridge and St. Mary's Hospital, University of London (now Imperial College). She worked under Geoffrey Rose in clinical medicine at St. Mary’s Hospital and subsequently in epidemiology at the London School of Hygiene and Tropical Medicine, with later clinical and academic posts in the University of London and University of California San Diego.  

Her research interests are the maintenance of health in later life and the causes and prevention of chronic diseases including cardiovascular disease, cancer and osteoporosis with a focus on nutrition, physical activity, and hormones. The research is based on longitudinal population studies and clinical trials.  

She is a principal investigator in the European Prospective Investigation in Cancer in Norfolk, part of a ten country half million participant research collaboration over two decades.  She is a Fellow of the Academy of Medical Sciences, UK and has a National Institutes of Health Research Senior Investigator award.

 

Continuing Excellence at the Heart of Cardiology – ESC publishing in 2015

The 2015 European Society of Cardiology Congress in London is in many ways the true highlight of the year for publishing in cardiology. Oxford University Press is delighted to be working with ESC again on what appears to be a bigger conference than ever before. Alongside the flagship European Heart Journal (now officially #2 in the world of cardiovascular medicine), we are showcasing some exciting new publications that are part of the ever-growing international ESC portfolio.

There are two new journals (EHJ-Cardiovascular Pharmacotherapy and EHJ-Quality of Care & Clinical Outcomes), as well as 4 major new ESC textbooks in, Intensive and Acute Cardiovascular CareCardiovascular ImagingPreventive Cardiology; and a beautiful, accessible case-based learning book with MCQs: The EHRA Book of Pacemaker, ICD, and CRT Troubleshooting. All are new for 2015 and available alongside the well-established ESC Textbook of Cardiovascular Medicine (Second Edition), The EAE Textbook of Echocardiography and the journal family, including Cardiovascular ResearchEuropean Heart Journal SupplementsEP-Europace and EHJ-Cardiovascular Imaging.

To give participants a taste of what’s new this year, don’t miss our series of Lightning Talks at the Oxford University Press stand (#B801) during lunch and coffee breaks. Every day during the Congress, ESC editors, authors, and advisors – all experts in their field – will give short talks about their work and experience.

Lightning Talks:

  • Professor Thomas Lüscher kicks-off the Lightning Talks at 16:00 on Saturday.

 

 

  • On Sunday Professor Jolanda van der Velden will speak, followed by Professor Marco Tubaro on STEMI systems of care and therapeutic strategies.
 

On Monday our line-up includes:

  • Professor Haran Burri who will present cases and brain teasers from his new book on device trouble shooting,

 

 

  • Professor Stefan Agewall who will introduce the new journal EHJ-Cardiovascular Pharmacotherapy,

 

 

  • Professor Pascal Vranckx and Professor Adam Timmis, who will share his experiences as a journal editor on low-level research misconduct. And for insights into the world of publishing in clinical medicine,

 

  • Ms. Rachel Fenwick from OUP will showcase our digital publishing platform Oxford Medicine Online, and

 

 

  • Mr Andy Sandland reveals all about Open Access Publishing during the breaks on Tuesday.

 

 

So don’t miss out – drop by the Oxford University Press stand to hear the speakers and discover everything that is on offer this year in cardiology, from definitive new textbooks with exclusive discounts, to free copies of all the ESC journals published by Oxford University Press.

 

The Russian National Congress of Cardiology 2015

The 2015 Congress will be held in Moscow, capital of the Russian Federation 22-25 September reports Prof Evgeny Shlyakhto

The Russian National Congress of Cardiology is a key annual event of the Russian Society of Cardiology, which gives an opportunity to discuss crucial issues of cardiovascular research and clinical practice on the multidisciplinary and international basis.

Today, the Russian Society of Cardiology is an all-Russian organization with more than 5,500 members and representations in about 60 regions of Russia. At the moment, 30 sections and 3 working groups are included in the Russian Society of Cardiology.

The Russian Society of Cardiology (RSC) is developing interdisciplinary approaches and aims to cooperate with other medical specialties. Among its members, there are internists, cardiovascular specialists, endocrinologists and other specialists interested in cardiovascular diseases.

The Russian National Congress of Cardiology has been held annually since 2000. Since 2012, one of the priorities for the RSC became its integration into the world cardiovascular community. Since that time there has been growing international participation, including leaders from the top world professional associations such as European Society of Cardiology and American College of Cardiology, which has become a new feature of the national event. This ensures an important contribution to its success as well as, to its scientific and educational value.

Today, the Russian National Congress of Cardiology is the key annual event of the most influential professional medical association in the country. The Congress scientific programme discusses the most significant modern achievements in prevention, diagnostics and treatment of cardiovascular diseases. The main topics include:

  • most demanding issues of emergency and elective cardiovascular care;
  • key problems in development and introduction of modern medical technologies into the primary and secondary prevention, diagnostics and treatment;
  • development of basic research: introducing the concept of translational medicine into cardiology;
  • improvement of pharmacotherapy following the latest evidence-based medical achievements;
  • modern imaging techniques in cardiology;
  • development of modern diagnostic methods (including prenatal methods) and technologies for the treatment of congenital cardiovascular defects and cardiology issues in perinatology and paediatrics;
  • development and introduction of new surgical interventions and hybrid technologies, problems of heart transplantation and innovations in the  treatment of cardiac arrhythmias;
  • co-morbidities in cardiology, geriatric aspects in cardiovascular diagnostics and treatment;
  • rehabilitation issues of cardiovascular patients and sports cardiology;
  • development of continuous medical education (CME) system in cardiology;
  • organization of nursery for cardiovascular patients.

The scientific programme traditionally consists of keynote lectures, plenary sessions, scientific symposia, workshops, poster sessions, a Young Cardiologist Award session, as well as training sessions with the possibility of receiving CME credits.

The 2014 Congress held in Kazan became the most significant event for the professional community: 170 scientific sessions and symposia, among them 12 plenary sessions, 11 educational seminars, 3 master classes, 3 discussion clubs and 3 round tables. In all about 4,500 delegates from 191 Russian cities and 29 foreign countries participated.

In 2015, the Russian National Congress of Cardiology will be held in Moscow, the capital of the Russian Federation, which hosts numerous of the most important events every year and well known for its traditional hospitality. The Congress guests will have an opportunity to get in touch with thousand years of Russian history and see the outstanding sights of one of the most beautiful cities in the world.

Evgeny Shlyakhto MD FESC

President of the Russian Society of Cardiology

e.shlyakhto@almazovcentre.ru

 

Back to top